Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pearl Therapeutics

Request full access

Develops a combination of products for the treatment of respiratory diseases, including chronic obstructive pulmonary disease

Redwood City, United StatesFounded 2006Biotech & Life Sciences

About Pearl Therapeutics

Pearl Therapeutics, a subsidiary of AstraZeneca, specializes in developing innovative respiratory therapies aimed at improving patient outcomes. Operating in the pharmaceutical and biotechnology market, Pearl Therapeutics focuses on creating advanced inhalation technology for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company serves healthcare providers and patients, leveraging its expertise in drug formulation and delivery systems to offer effective treatment options. Pearl Therapeutics generates revenue through the development and commercialization of its proprietary respiratory therapies, often in collaboration with its parent company, AstraZeneca. The business model includes research and development, clinical trials, regulatory approvals, and market distribution. By addressing unmet medical needs in respiratory care, Pearl Therapeutics aims to enhance the quality of life for patients worldwide.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
53
Open positions
None listed
Dealroom signal
31.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Respiratory, Pulmonary, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jun 2013 $1.2B — AstraZeneca —
LATE VCOther financing Apr 2013 $42M $167M New Leaf Venture Partners · 5AM Ventures · Clarus Ventures · Vatera Healthcare Partners —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Pearl Therapeutics website traffic

Latest recorded traffic for Pearl Therapeutics is 110 monthly website visits. Pearl Therapeutics's team declined 29.3% over the past year.

Latest monthly visits110 1-year team growth-29.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Pearl Therapeutics in the Redwood City ecosystem

Live from Dealroom

The Pearl Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • New Leaf Venture Partners
  • Nektar Therapeutics

Series B and later5 investors entered at this stage

  • Oxford Finance
  • Standard Treasury
  • Vatera Healthcare Partners
  • 5AM Ventures
  • Clarus Ventures

Other known investors1 additional known investor

  • AstraZeneca
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Redwood City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pearl Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pearl Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.